Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

Slides:



Advertisements
Similar presentations
THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*
Advertisements

Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Farxiga™ - Dapagliflozin
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin.
Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田 昌文 Matsuda, Masafumi.
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes Featured Article: Michaela Diamant, Michael A.
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.
Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial Featured Article: Ravi Retnakaran, Caroline K.
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.
Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes.
Part 10. FPG (mg/dL) BaselineDay 8Day 15 Vehicle (n=6) 0.01 mg/kg (n=6) 0.1 mg/kg (n=6) 1 mg/kg (n=6) 10 mg/kg (n=6) *P
Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free- Living, Randomized Clinical Trial Featured Article: Roman Hovorka,
Adding Prandial Insulin to Basal Insulin: Key Challenges
Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,
Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.
Diabetes Prevention Program (DPP)
Int J Clin Pract, December 2013, 67, 12,
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.
Sglt-2 insulin Matthews D, Fulcher G, Perkovic V, et al. Ef  cacy and safety of canagliflozin,an inhibitor of sodium glucose co-transporter 2, added.
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
Angelo L Gaffo Kenneth G Saag Core Evidence 2009:4 25–36
Thrice-Weekly Glatiramer Acetate for Relapsing Forms of Multiple Sclerosis: Findings from the GALA Study Fred D. Lublin, MD Saunders Family Professor of.
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.
Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:
Featured Article: Wayne H.-H. Sheu, Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Arpana Mirza, Barry J. Goldstein, Keith D. Kaufman, and Samuel S. Engel.
Date of download: 6/24/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.
Date of download: 6/24/2016 From: Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis Ann Intern Med.
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,
 Insulin Degludec  Ultra long action  Due to formation of soluble multihexamers at the injection site from which monomers gradually separate and are.
Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes Featured Article: Jennifer.
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose- Ranging.
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
Phase 3 Treatment Experienced
Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3
Key publication slides
Neal B, et al. Diabetes Care 2015;38:403–411
Dapagliflozin Improves Hyperglycemia and Beta-Cell Function Without Increasing Hypoglycemic Episodes in Patients With Type 2 Diabetes Mellitus Afshin Salsali.
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.
Phase 2 Treatment Naïve Injection Drug Use
Patient disposition for the double-blind study period.
GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.
Diabetes Journal Club Julie Shah.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.
EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.
Pramlintide Synthetic analog of the β-cell hormone amylin
SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,
Novel Approaches to T1D Management
Dual SGLT1/SGLT2 Inhibition in T1D
Screening, Lipid Stabilization, and Placebo Run-in
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Guidelines for Initiation of Therapy
(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.
Flow of Patients Through Trial
RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Pramlintide Therapy Part 1of 2
Effect of empagliflozin on efficacy parameters at week 18.
Glycemic control and body weight over 52 weeks.
Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.
Presentation transcript:

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article: Robert R. Henry, Payal Thakkar, Cindy Tong, David Polidori, and Maria Alba Diabetes Care Volume 38: Volume 38: December, 2015

STUDY OBJECTIVE To assess the efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in adults with type 1 diabetes Henry R.R. et al. Diabetes Care 2015;38:

STUDY DESIGN AND METHODS 18-week, double-blind, phase 2 study randomized 351 patients on multiple daily insulin injections or continuous subcutaneous insulin infusion to canagliflozin 100 or 300 mg or placebo Primary end point was the proportion of patients achieving at week 18 both an HbA 1c reduction from baseline of ≥0.4% and no increase in body weight Other end points included changes in HbA 1c, body weight, and insulin dose, as well as hypoglycemia incidence Safety was assessed by adverse event (AE) reports Henry R.R. et al. Diabetes Care 2015;38:

RESULTS More patients had both HbA 1c reduction ≥0.4% and no increase in body weight with canagliflozin 100 and 300 mg versus placebo at week 18 Both canagliflozin doses provided reductions in HbA 1c, body weight, and insulin dose versus placebo over 18 weeks Incidence of hypoglycemia was similar across groups Severe hypoglycemia rates were low (1.7–6.8%) Overall incidence of AEs was 55.6, 67.5, and 54.7% with canagliflozin 100 and 300 mg and placebo, respectively Discontinuation rates were low (0.9–1.3%) Increased incidence of ketone-related AEs was seen with canagliflozin 100 and 300 mg versus placebo Henry R.R. et al. Diabetes Care 2015;38:

CONCLUSIONS Canagliflozin provided reductions in HbA 1c, body weight, and insulin dose with no increase in hypoglycemia There were increased rates of ketone-related AEs, including diabetic ketoacidosis, in adults with type 1 diabetes inadequately controlled with insulin Henry R.R. et al. Diabetes Care 2015;38: